47 Drugs antagonizing the 5-HT2A/C receptor increase SWS, whereas 5-HT2A/C agonists have the opposite effect.48 Spectral analysis of selleck chemical Paclitaxel non-REM sleep shows a huge increase in slow wave activity with compounds blocking 5-HT2A/C transmission.49, 50 Although some antidepressant and antipsychotic drugs display this Inhibitors,research,lifescience,medical 5-HT2A/C antagonist profile and indeed have been shown to increase SWS,51, 52 up to now there is no drug marketed for sleep disorder that enhances SWS in a sustained manner. In contrast, chronic benzodiazepine administration has been shown to decrease SWS.53 New nonbenzodiazepine hypnotics acting at. the GABAA receptor, such as zopiclone,

Zolpidem, and zaleplon, have a more favorable profile in terms of sleep architecture, although none of them has demonstrated sustained SWS enrichment

after repeated administration.54 In this regard, 5-HT2A/C receptor antagonists could thus be of great interest, for alleviating age-related Inhibitors,research,lifescience,medical sleep disturbances and for ameliorating psychomotor and cognitive functions by restoring deep SWS, particularly in elderly insomniacs. There is preliminary evidence to suggest that repeated administration of ritanserin 5 mg (a 5-HT2A/C receptor antagonist) in middle-aged poor sleepers decreases the Inhibitors,research,lifescience,medical frequencies of awakening and improves subjective quality of sleep55 and increases subjective alertness Inhibitors,research,lifescience,medical in narcoleptic patients56 and in young healthy volunteers performing a driving test.57 Furthermore, in young healthy subjects, Gronfier et al58 found that, the SWS enrichment induced by the acute administration of ritanserin 5 mg is positively correlated to the amount of GH secretion, suggesting a common 5-HT2a/c-triggered stimulatory mechanism between GH secretion and delta wave activity. Inhibitors,research,lifescience,medical The question of whether antagonizing

the 5-HT2A or 5-HT2C receptor allows SWS enhancement is still they unresolved. There are some data suggesting that 5-HT2C mediates SWS,59, 60 but Landolt et al49 showed substantial SWS enhancement with SR 46349B, a specific 5-HT2A antagonist. Clozapine, which displays a weaker activity Entinostat for 5HT2A receptors, does not seem to affect, SWS in schizophrenic patients or even tends to diminish it. Olanzapine induces clear-cut, SWS enhancement in healthy subjects61-67; these effects seem to be mediated by 5-HT2C receptors, since allelic differences in the gene coding for this receptor influence SWS responses to olanzapine.63 In summary, compounds antagonizing 5-HT2A/C receptors could be valuable drugs for age -related sleep disturbances. In healthy subjects, studying drug-induced SWS alteration is a particularly useful tool for the development of CNSacting compounds with 5-HT2A/C-blocking properties.